Health Status of Children Born After Assisted Reproductive Technologies
Health Status of Children Born After Assisted Reproductive Technologies With the Development of Prediction Model and Principles of Child Management.
The goal of this observational study is to study the features of psychophysical development and the morbidity patterns of children born after assisted pregnancy, and to identify the connection with the health status of mothers, followed by the development of a prediction model and general principles of management of children born after ART. The main questions it aims to answer are: • the influence of premorbid background of mothers on children's physical development, disease occurrence and morbidity patterns of children born as after ART.
- To identify the indicators of cellular and humoral immunity in children born after different oocyte fertilization methods in IVF programs (classical IVF or ICSI).
- To study the long-term effects of ART on the endocrine status of children.
It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
Study Overview
Status
Intervention / Treatment
Detailed Description
The tasks of the planned scientific and engineering project are based on the study of health status of children born after ART. The presence of a large cohort of children after ART in Kazakhstan will allow us to study morbidity patterns with the connection of mother's anamnesis, as well as to develop a prediction model and algorithms for the management of children conceived by assisted pregnancy. A comprehensive assessment of the health status of children born after ART will make it possible to determine the effect of the method of conception on the risks of immunity-related diseases and endocrine system pathology. It will allow us to predict deviations and ensure timely access to specialists and further examination. The presence of a burdened psychological background in couples with infertility may further influence the psychosocial adaptation of children conceived by ART and/or provoke higher morbidity rates in this group of children. It is important for the healthy and full integration of these children into society, including successful professional development in the future.
2.2. The project objective: to study the features of psychophysical development and the morbidity patterns of children born after assisted pregnancy, and to identify the connection with the health status of mothers, followed by the development of a prediction model and general principles of management of children born after ART.
Project Tasks
- To study the influence of premorbid background of mothers on children's physical development, disease occurrence and morbidity patterns of children based on a retrospective study of 120 medical records of mothers and their children born as after ART.
- To determine the indicators of cellular and humoral immunity (hemogram examination, cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) in children born after ART.
- To study the long-term effects of the hormone therapy in 120 mothers on the endocrine status (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) of children born after ART.
- To develop a prediction model and algorithms for the management of children born after ART.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Almaty, Kazakhstan, 050044
- Scientific Center of Pediatrics and Pediatric Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- successful ART program after IVF and ICSI,
- the transfer of fresh and frozen-thawed embryos (FET)
- a single or multiple pregnancy
- the birth of a child in the period from 2017 to 2023.
Exclusion Criteria:
- intrauterine insemination
- ART programs with donor gametes
- surrogacy.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
children born after ART
120 children born after assisted reproductive technologies
|
It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART.
Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
Other Names:
|
|
children conceived spontaneously
132 children conceived spontaneously
|
It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART.
Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immune status of children born after assisted reproductive technologies
Time Frame: 1 day over which each participant is assessed
|
hemogram examination(leycosytes, lymphosytes), immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG)
|
1 day over which each participant is assessed
|
|
laboratory investigations in endocrine system
Time Frame: 1 day over which each participant is assessed
|
TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium
|
1 day over which each participant is assessed
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anthropometric measures
Time Frame: 1 day over which each participant is assessed
|
assessment of Weight-for-age (kg), Weight-for-length/height, assessment of Length/height-for-age (cm), assessment of Head circumference for age (cm)
|
1 day over which each participant is assessed
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sevara K Ilmuratova, Kazakhstan Medical University "KSPH"
- Study Chair: Vyacheslav Lokshin, PhD, International Clinical Centre of Reproduction "PERSONA"
- Study Chair: Lyazzat Manzhuova, PhD, Scientific Center of Pediatrics and Pediatric Surgery
- Principal Investigator: Zhanar Nurgaliyeva, PhD, Asfendiyarov Kazakh National Medical University
- Principal Investigator: Farida Kussainova, MD, Asfendiyarov Kazakh National Medical University
- Study Director: Аygul Bazarbaeva, MD, Scientific Center of Pediatrics and Pediatric Surgery
- Principal Investigator: Valeriya Nekhorosheva, MD, Institute of Reproductive Medicine
- Principal Investigator: Aygerim Abshekenova, MD, International Clinical Centre of Reproduction "PERSONA"
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ИРН AP14872103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.